<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04820049</url>
  </required_header>
  <id_info>
    <org_study_id>GNI-F573-202001</org_study_id>
    <nct_id>NCT04820049</nct_id>
  </id_info>
  <brief_title>F573 Ia Clinical Trial</brief_title>
  <official_title>F573 for Injection Phase Ia Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Continent Pharmaceutical Co, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Continent Pharmaceutical Co, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tolerance and PK study of F573&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The tolerance and PK study of single dose and multi dose F573.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD of F573 in health people</measure>
    <time_frame>up to 7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of F573 in health people</measure>
    <time_frame>up to 7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of F573 in health people</measure>
    <time_frame>up to 7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of F573 in health people</measure>
    <time_frame>up to 7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of F573 in health people</measure>
    <time_frame>up to 7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Tolerance</condition>
  <condition>Pharmacokinetic</condition>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>F573 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F573</intervention_name>
    <description>F573 for injection</description>
    <arm_group_label>F573 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Water for injection</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria (each item must be met)&#xD;
&#xD;
          1. Healthy volunteers, male and female;&#xD;
&#xD;
          2. Age: 18-45 years old;&#xD;
&#xD;
          3. Weight: male ≥50kg, female ≥45kg, 19≤BMI≤26 (BMI= weight (kg)/height 2 (m2));&#xD;
&#xD;
          4. Passed the comprehensive physical examination, that is, the routine blood and urine,&#xD;
             blood pregnancy, blood glucose, blood lipids, blood electrolytes, hepatitis B surface&#xD;
             antigen, liver and kidney function, hepatitis C, HIV and syphilis antibody test,&#xD;
             electrocardiogram, cigarette test, urine drug screening, alcohol breath test, chest&#xD;
             X-ray and other abnormal or abnormal without clinical significance;&#xD;
&#xD;
          5. Have a detailed understanding of the nature, significance, possible benefits, possible&#xD;
             inconveniences and potential risks of the trial before the study, and voluntarily&#xD;
             participate in the clinical trial, be able to communicate well with the researchers,&#xD;
             comply with the requirements of the whole study, and have the ability to understand&#xD;
             and sign the written informed consent.&#xD;
&#xD;
        Exclusion criteria (if one of them is met)&#xD;
&#xD;
          1. Participated in any other clinical trials within the three months prior to the trial;&#xD;
&#xD;
          2. (preliminary) of any process may affect test security, or drug in the body of the&#xD;
             disease, including but not limited to: heart, liver, kidney, endocrine, the digestive&#xD;
             tract, immune system and respiratory system always or the existing system diseases&#xD;
             (especially cardiovascular diseases including cardiovascular disease risk, any impact&#xD;
             on drug absorption of gastrointestinal diseases (such as irritable bowel syndrome,&#xD;
             inflammatory bowel disease), active pathological bleeding (such as peptic ulcer),&#xD;
             urticaria, eczema, dermatitis, epilepsy, allergic rhinitis, asthma, etc.);&#xD;
&#xD;
          3. (Inquiry) Allergic constitution: if there is a history of drug, food allergy or skin&#xD;
             allergy;&#xD;
&#xD;
          4. (Inquiry) Use of any drug that inhibits or induces liver metabolism to the drug within&#xD;
             28 days prior to use of the study drug (Common liver enzyme inducers: barbiturates&#xD;
             such as phenobarbital, carbamazepine, aminomide, griseofulvin, metalpropanol,&#xD;
             phenytoin, glumide, rifampicin, dexamethasone; Common liver enzyme inhibitors:&#xD;
             chlorpromazine, cimetidine, ciprofloxacin, metronidazole, chloramphenicol, isoniazid,&#xD;
             sulfonamides);&#xD;
&#xD;
          5. Have used any medicine (including Chinese herbal medicine) and health care products&#xD;
             within 14 days before the first administration;&#xD;
&#xD;
          6. (Consultation) People who have special requirements for food and cannot abide by the&#xD;
             unified diet (such as intolerance to standard food);&#xD;
&#xD;
          7. (consultation) can not tolerate venipuncture, intramuscular injection and/or have a&#xD;
             history of dizziness of blood and needles;&#xD;
&#xD;
          8. (Consultation) Drinking excessively tea, coffee or caffeinated beverages for a long&#xD;
             time in the past (more than 8 cups a day, 1 cup =250mL); Or study within 48 hours&#xD;
             before the first administration of the drug, the intake of any food or beverage&#xD;
             containing caffeine (such as coffee, strong tea, chocolate, etc.) and other special&#xD;
             diet that affects the absorption, distribution, metabolism, excretion of the drug;&#xD;
&#xD;
          9. (Inquiry) Previous alcohol abuse (i.e., more than 28 SUs per week for men and more&#xD;
             than 21 SUs per week for women (1 SU contains 14 g of alcohol, such as 360 mL beer or&#xD;
             45 mL 40% spirits or 150 mL wine); Or regular alcohol consumption (more than 14&#xD;
             standard units per week) in the 6 months prior to the study; Or have taken any&#xD;
             alcoholic product within 24 hours prior to first administration;&#xD;
&#xD;
         10. (Inquiry) who donated blood or suffered massive bleeding (greater than 450 mL) within&#xD;
             3 months before the first administration of the study, or who planned to donate blood&#xD;
             or blood components during the study or within 3 months after the end of the study;&#xD;
&#xD;
         11. (Inquiry) Acute disease occurs in the pre-study screening stage or before the study&#xD;
             medication;&#xD;
&#xD;
         12. (Inquiry) Those who took food or beverage (such as grapefruit, mango, dragon fruit,&#xD;
             grape juice, orange juice and other rich flavonoids or citrus compounds) containing&#xD;
             enzymes that can induce or inhibit liver metabolism within 24 hours before the first&#xD;
             administration of medication;&#xD;
&#xD;
         13. (Consultation) had surgery within 3 months prior to the screening period, or planned&#xD;
             to have surgery during the study period;&#xD;
&#xD;
         14. (Inquiry) Previous history of drug abuse; With a history of drug abuse;&#xD;
&#xD;
         15. Smoking more than 5 cigarettes per day in the 14 days before screening, or unable to&#xD;
             stop using any tobacco products during the trial;&#xD;
&#xD;
         16. Screening (Consultation) Those who smoked or used any tobacco products during the&#xD;
             admission period;&#xD;
&#xD;
         17. Positive results of nicotine test;&#xD;
&#xD;
         18. Alcohol breath test with test results greater than 0.0mg/100mL;&#xD;
&#xD;
         19. Positive urine drug screening;&#xD;
&#xD;
         20. Pregnant or lactating women;&#xD;
&#xD;
         21. Those who had family planning during the study period and within 6 months after the&#xD;
             end of the study;&#xD;
&#xD;
         22. Refusing to use non-drug contraception during the study period&#xD;
&#xD;
         23. novel coronavirus nucleic acid test positive or antibody test positive;&#xD;
&#xD;
         24. The investigator considers that there is any circumstance that may affect the&#xD;
             subject's ability to give informed consent or follow the study protocol, or that the&#xD;
             participant's participation in the study may affect the study result or their own&#xD;
             safety.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rui Zhang, Dr.</last_name>
      <phone>15527272759</phone>
      <email>392519821@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 3, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

